Literature DB >> 29599203

Successful treatment of disseminated Rosai-Dorfman disease with siltuximab.

Hannah Lee1, Gentry King2, Kavita Garg3, Zenggang Pan4, Jennifer Tobin5, William A Robinson2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29599203      PMCID： PMC6029547          DOI： 10.3324/haematol.2018.188441

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Dramatic clinical efficacy of cladribine in Rosai-Dorfman disease and evolution of the cytokine profile: towards a new therapeutic approach.

Authors:  Achille Aouba; Benjamin Terrier; Viorel Vasiliu; Sophie Candon; Nicole Brousse; Bruno Varet; Olivier Hermine
Journal:  Haematologica       Date:  2006-12       Impact factor: 9.941

Review 2.  Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity.

Authors:  E Foucar; J Rosai; R Dorfman
Journal:  Semin Diagn Pathol       Date:  1990-02       Impact factor: 3.464

3.  Successful treatment of refractory cutaneous Rosai-Dorfman disease with vincristine.

Authors:  Ping Liu; Pei Wang; Juan Du; Jianzhong Zhang
Journal:  J Dermatol       Date:  2014-11-25       Impact factor: 4.005

4.  Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.

Authors:  Sofia Garces; L Jeffrey Medeiros; Keyur P Patel; Shaoying Li; Sergio Pina-Oviedo; Jingyi Li; Juan C Garces; Joseph D Khoury; C Cameron Yin
Journal:  Mod Pathol       Date:  2017-06-30       Impact factor: 7.842

5.  Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Frits van Rhee; Raymond S Wong; Nikhil Munshi; Jean-Francois Rossi; Xiao-Yan Ke; Alexander Fosså; David Simpson; Marcelo Capra; Ting Liu; Ruey Kuen Hsieh; Yeow Tee Goh; Jun Zhu; Seok-Goo Cho; Hanyun Ren; James Cavet; Rajesh Bandekar; Margaret Rothman; Thomas A Puchalski; Manjula Reddy; Helgi van de Velde; Jessica Vermeulen; Corey Casper
Journal:  Lancet Oncol       Date:  2014-07-17       Impact factor: 41.316

6.  Rosai-Dorfman Disease with Activating KRAS Mutation - Response to Cobimetinib.

Authors:  Eric Jacobsen; Vignesh Shanmugam; Jyothi Jagannathan
Journal:  N Engl J Med       Date:  2017-12-14       Impact factor: 91.245

7.  The Rosai-Dorfman disease histiocytes are not infected by Epstein-Barr virus.

Authors:  W Y Tsang; T T Yip; J K Chan
Journal:  Histopathology       Date:  1994-07       Impact factor: 5.087

Review 8.  Rosai-Dorfman disease treated with methotrexate and low-dose prednisone: case report and review of the literature.

Authors:  Eiman Nasseri; Annie Belisle; Deana Funaro
Journal:  J Cutan Med Surg       Date:  2012 Jul-Aug       Impact factor: 2.092

9.  Cutaneous Destombes-Rosai-Dorfman disease: absence of detection of HHV-6 and HHV-8 in skin.

Authors:  N Ortonne; A M Fillet; H Kosuge; M Bagot; C Frances; Janine Wechsler
Journal:  J Cutan Pathol       Date:  2002-02       Impact factor: 1.587

10.  Extranodal rosai-dorfman disease of the bone treated with surgery and radiotherapy.

Authors:  Nitesh N Paryani; Larry C Daugherty; Mary I O'Connor; Liuyan Jiang
Journal:  Rare Tumors       Date:  2014-12-11
View more
  1 in total

1.  [Rosai-Dorfman disease: a clinicopathologic analysis and whole exome sequencing in 23 cases].

Authors:  W J Fu; J Du; J Lu; L Z Wang; J M Yang; M X He; X X Hu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2019-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.